Evotaz Europos Sąjunga - vengrų - EMA (European Medicines Agency)

evotaz

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv fertőzések - vírusellenes szerek szisztémás alkalmazásra - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 és 5.

Aivlosin Europos Sąjunga - vengrų - EMA (European Medicines Agency)

aivlosin

eco animal health europe limited - tilvalozin - antiinfectives szisztémás használatra, szisztémás antibakteriális szerek, makrolidok - pheasants; chicken; turkeys; pigs - pigstreatment, methaphylaxis sertés enzootikus tüdőgyulladás;kezelés sertés proliferatív enteropathia (ileitis); - kezelés, - methaphylaxis sertés vérhas. chickenstreatment, methaphylaxis légúti betegség társul mycoplasma gallisepticum a csirkék. pheasantstreatment légúti betegség társul mycoplasma gallisepticum. turkeystreatment légúti betegség társul tylvalosin érzékeny törzsek ornithobacterium rhinotracheale pulyka.

Naxcel Europos Sąjunga - vengrų - EMA (European Medicines Agency)

naxcel

zoetis belgium sa - ceftiofurra - baktériumellenes szerek szisztémás alkalmazásra - pigs; cattle - pigstreatment of bacterial respiratory disease associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis and streptococcus suis. streptococcus suis fertőzéssel összefüggő szeptikémia, polyarthritis vagy poliszérositis kezelése. cattletreatment of acute interdigital necrobacillosis in cattle also known as panaritium or foot rot. szarvasmarhákban előforduló akut postpartum (puerperális) metritis kezelése olyan esetekben, amikor a másik antimikrobiális kezelés sikertelen.

Jakavi Europos Sąjunga - vengrų - EMA (European Medicines Agency)

jakavi

novartis europharm limited - ruxolitinib (foszfát formájában) - myeloproliferative disorders; polycythemia vera; graft vs host disease - daganatellenes szerek - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi kezelésére javallt felnőtt betegek polycythaemia vera, aki ellenáll, vagy érzékeny a hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Heplisav B Europos Sąjunga - vengrų - EMA (European Medicines Agency)

heplisav b

dynavax gmbh - hepatitis b felületi antigén - hepatitisz b - a vakcinák - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.